Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Calidi Biotherapeutics ( (CLDI) ) is now available.
On March 6, 2026, Calidi Biotherapeutics, Inc. entered an underwriting agreement with Ladenburg Thalmann for an underwritten public offering of 2,278,731 common stock units and 9,815,900 pre-funded warrant units, raising about $6.03 million in gross proceeds. The units, priced at $0.50 for common stock units and $0.499 for pre-funded units, included multiple series of immediately exercisable common stock warrants with structured reset features, and the company plans to use the funds for working capital and general corporate purposes.
The offering, which closed on March 9, 2026, also granted the underwriter a warrant for up to 604,732 shares and imposed short-term restrictions on Calidi’s ability to issue additional equity or enter variable-rate financings, while directors and executives agreed to 90-day lock-ups. Separately, on March 5, 2026, Calidi amended terms of existing Series G, H and I warrants, cutting their exercise price to $0.50 per share, a move that, together with the new issuance, reshapes the company’s capital structure and increases potential equity dilution for existing shareholders, with 10,545,725 common shares outstanding as of March 11, 2026.
The most recent analyst rating on (CLDI) stock is a Sell with a $0.93 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.
The score is held down primarily by persistent losses and significant cash burn with no revenue base, despite improved leverage and positive equity. Technicals also remain broadly bearish (below key moving averages and negative MACD), while corporate events provide a modest offset through financing and encouraging preclinical progress. Valuation contributes little given the negative P/E and no dividend yield.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. is a San Diego-based biotechnology company focused on developing targeted genetic medicines for cancer. Its proprietary Redtail platform uses an engineered enveloped oncolytic virus designed for systemic delivery to metastatic tumor sites, with lead candidate CLD-401 in IND-enabling studies for non-small cell lung cancer, head and neck cancer and other hard-to-treat tumors.
The company aims to leverage this platform to deliver virotherapy and genetic payloads, including BiTE-based approaches, to solid tumors with high unmet medical need. Calidi is listed on the NYSE American under the ticker CLDI and positions itself in the oncology space, targeting metastatic disease where conventional treatments often fall short.
Average Trading Volume: 175,110
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.58M
See more insights into CLDI stock on TipRanks’ Stock Analysis page.